133 related articles for article (PubMed ID: 17584566)
1. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Bhatt DL; Chew DP; Grines C; Mukherjee D; Leesar M; Gilchrist IC; Corbelli JC; Blankenship JC; Eres A; Steinhubl S; Tan WA; Resar JR; AlMahameed A; Abdel-Latif A; Tang WH; Brennan D; McErlean E; Hazen SL; Topol EJ
Am Heart J; 2007 Jul; 154(1):137-43. PubMed ID: 17584566
[TBL] [Abstract][Full Text] [Related]
2. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
Grey A; Bolland M; Gamble G; Wattie D; Horne A; Davidson J; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1305-10. PubMed ID: 17264176
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome.
Cao Z; Zhou YJ; Zhao YX; Liu YY; Guo YH; Cheng WJ
Chin Med J (Engl); 2006 Jul; 119(14):1171-5. PubMed ID: 16863608
[TBL] [Abstract][Full Text] [Related]
6. Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial.
Christoph M; Herold J; Berg-Holldack A; Rauwolf T; Ziemssen T; Schmeisser A; Weinert S; Ebner B; Ibrahim K; Strasser RH; Braun-Dullaeus RC
Cardiology; 2015; 131(3):165-71. PubMed ID: 25967848
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
8. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
9. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
[TBL] [Abstract][Full Text] [Related]
10. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
11. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
Werner C; Kamani CH; Gensch C; Böhm M; Laufs U
Diabetes; 2007 Oct; 56(10):2609-15. PubMed ID: 17623816
[TBL] [Abstract][Full Text] [Related]
12. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial.
Boggild AK; Krudsood S; Patel SN; Serghides L; Tangpukdee N; Katz K; Wilairatana P; Liles WC; Looareesuwan S; Kain KC
Clin Infect Dis; 2009 Sep; 49(6):841-9. PubMed ID: 19673614
[TBL] [Abstract][Full Text] [Related]
13. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
15. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
[TBL] [Abstract][Full Text] [Related]
17. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
Yi Z; Fan X; Wang J; Liu D; Freudenreich O; Goff D; Henderson DC
Psychiatry Res; 2012 Dec; 200(2-3):79-82. PubMed ID: 22727707
[TBL] [Abstract][Full Text] [Related]
19. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
